| Dr Shiwan Kamal Shah, DO | |
|
301 University Blvd, Galveston, TX 77555-2608 | |
| (409) 772-2222 | |
| Not Available |
| Full Name | Dr Shiwan Kamal Shah |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 18 Years |
| Location | 301 University Blvd, Galveston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881898476 | NPI | - | NPPES |
| 3851804202 | Other | MYUTMB 3851804202-COMMERCIAL NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | N2793 (Texas) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | N2793 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Texas Medical Branch Galveston | Galveston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Texas Medical Branch Faculty Group Practice | 3375456734 | 875 |
News Archive
Speaker Nancy Pelosi released the following statement on a new report released today by the Center for American Progress that shows that health insurance reform will create up to 4 million more jobs over the next decade than would be created without reform. The report finds that health care reform could increase the number of jobs in the United States by about 250,000 to 400,000 per year over the coming decade.
Stroke is the third leading cause of death and a major source of disability in the United States. Every year about 700,000 people in the United States suffer a stroke, resulting in nearly 158,000 deaths.
Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TRI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TRI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance.
William Meehan, MD, is the first recipient of the AMSSM Foundation-ACSM Foundation Clinical Research Grant for his research titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Transcranial Light Emitting Diode Therapy for the Treatment of Chronic Concussive Brain Injury."
The raging coronavirus pandemic is causing immense fear and uncertainty across the world. One of the most distressing aspects of COVID-19 disease is the seemingly large number of unknowns. These include the burning question of immunity. Does a person who was sick with the COVID-19 and then recovered or was infected without symptoms, have immunity against re-infection?
› Verified 2 days ago
| Entity Name | Utmb Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241146 PECOS PAC ID: 3375456734 Enrollment ID: O20031112000438 |
News Archive
Speaker Nancy Pelosi released the following statement on a new report released today by the Center for American Progress that shows that health insurance reform will create up to 4 million more jobs over the next decade than would be created without reform. The report finds that health care reform could increase the number of jobs in the United States by about 250,000 to 400,000 per year over the coming decade.
Stroke is the third leading cause of death and a major source of disability in the United States. Every year about 700,000 people in the United States suffer a stroke, resulting in nearly 158,000 deaths.
Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TRI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TRI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance.
William Meehan, MD, is the first recipient of the AMSSM Foundation-ACSM Foundation Clinical Research Grant for his research titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Transcranial Light Emitting Diode Therapy for the Treatment of Chronic Concussive Brain Injury."
The raging coronavirus pandemic is causing immense fear and uncertainty across the world. One of the most distressing aspects of COVID-19 disease is the seemingly large number of unknowns. These include the burning question of immunity. Does a person who was sick with the COVID-19 and then recovered or was infected without symptoms, have immunity against re-infection?
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shiwan Kamal Shah, DO 301 University Blvd, Galveston, TX 77555-5302 Ph: (409) 772-2222 | Dr Shiwan Kamal Shah, DO 301 University Blvd, Galveston, TX 77555-2608 Ph: (409) 772-2222 |
News Archive
Speaker Nancy Pelosi released the following statement on a new report released today by the Center for American Progress that shows that health insurance reform will create up to 4 million more jobs over the next decade than would be created without reform. The report finds that health care reform could increase the number of jobs in the United States by about 250,000 to 400,000 per year over the coming decade.
Stroke is the third leading cause of death and a major source of disability in the United States. Every year about 700,000 people in the United States suffer a stroke, resulting in nearly 158,000 deaths.
Envoy Therapeutics, Inc., a newly formed drug discovery company, today announced that it has secured a loan from Takeda Research Investment (TRI) which Envoy may elect to convert to Envoy preferred stock should the company complete a second private equity financing. TRI will receive certain rights from Envoy related to a specific therapeutic field while scientists at the two companies craft a broad scientific research alliance.
William Meehan, MD, is the first recipient of the AMSSM Foundation-ACSM Foundation Clinical Research Grant for his research titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Transcranial Light Emitting Diode Therapy for the Treatment of Chronic Concussive Brain Injury."
The raging coronavirus pandemic is causing immense fear and uncertainty across the world. One of the most distressing aspects of COVID-19 disease is the seemingly large number of unknowns. These include the burning question of immunity. Does a person who was sick with the COVID-19 and then recovered or was infected without symptoms, have immunity against re-infection?
› Verified 2 days ago
Dr. James Harold Pavela, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-7063 Fax: 409-747-8579 | |
Diaa Hamouda, MBBCH Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 301 University Blvd, Jsa 9.128, Galveston, TX 77555 Phone: 409-772-8031 Fax: 409-772-6940 | |
Syed Mustajab Hasan, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1005 Harborside Drive, Galveston, TX 77555 Phone: 409-762-2328 Fax: 832-632-7866 | |
Arielle Degueure, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-747-1883 Fax: 409-747-8579 | |
Dr. Shawn Pua Eiko Nishi, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-643-4587 | |
Suyuan Tan, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-747-1883 | |
Shahzad Jokhio, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-722-2222 |